ribosomal protein S4X pseudogene 18Genealiases: RPS4P18 · RPS4X_10_1587
Q-omics provides the consensus-scored RPS4XP18 profile across patient tissues and cancer cell-line models. RPS4XP18 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, RPS4XP18 is differentially expressed in 6, with the highest sampling consensus in STAD. Additionally, RPS4XP18 RNA expression shows 8,208 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight COAD, STAD, and LSCC as cancer lineages where RPS4XP18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS4XP18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS4XP18 survival associations across molecular data types. RPS4XP18 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS4XP18 RNA expression–survival associations across cancer types. High RPS4XP18 expression shows unfavorable associations in COAD, TGCT, KIRC, STAD and ACC, but favorable associations in LIHC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for RPS4XP18 RNA expression.
This table summarizes RPS4XP18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS4XP18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS4XP18 shows lower tumor expression in BRCA and higher tumor expression in STAD, CHOL, LUSC, LIHC and COAD. The STAD box plot shows higher RPS4XP18 RNA expression in tumor versus normal tissue (log2 FC = +0.107, t-test p = .042).
This table shows molecular features associated with RPS4XP18 in patient tissues and cancer cell lines. In patient samples, RPS4XP18 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
